Navigation Links
Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
Date:6/9/2009

dose study demonstrated:

  • No serious adverse events or discontinuations;
  • No dose-related adverse events;
  • No grade III / IV lab abnormalities;
  • No clinically significant changes in vital signs or ECGs.

A Phase 1b multiple ascending dose trial has now been initiated in patients with chronic HCV genotype 1 infection. Subjects will be enrolled at multiple centers and randomized to PSI-7851 (8 per cohort) or placebo (2 per cohort). Based upon the results from the SAD study, the first dose of PSI-7851 to be tested will be 50mg once daily. The primary objective is to assess the safety, tolerability and pharmacokinetics of PSI-7851 after repeat dosing over 3 days. The secondary objective is to evaluate the decrease in HCV RNA.

Results from both studies are expected in the second half of 2009.

About PSI-7851

PSI-7851 is a uridine nucleotide analog currently in development for the treatment of chronic HCV infection. PSI-7851 has demonstrated potent in vitro anti-HCV activity with EC50 values of 90 +/- 60 nM, which is approximately 15- to 20-fold more potent than Pharmasset's first generation nucleoside polymerase inhibitor, R7128. In vitro studies of PSI-7851 have not shown evidence of any mitochondrial or other cellular toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in primary human hepatocytes is approximately 38 hours, which suggests the possibility for once-daily dosing. Like R7128, PSI-7851 has demonstrated in vitro activity against all of the most common HCV genotypes.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Pharmassets Underwriters Release Shares from Lock-Up
2. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
3. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
4. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
5. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
6. Pharmasset to Webcast an Investor Event from the AASLD Meeting
7. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
8. Pharmasset to Present at Two Upcoming Investor Conferences
9. Pharmasset to Present at Two Upcoming Investor Conferences
10. Pharmasset to Present at Deutsche Bank Healthcare Conference
11. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... of Medicine researchers have made an important advancement ... potentially deadly tick-transmitted disease, human granulocytic anaplasmosis (HGA). ... seen a steady rise in the incidence of ... making the need for a vaccine critical. Successful ... to prevent disease, and the VCU team has ...
(Date:7/29/2014)... A team of scientists, led by Western ... developed a blood test for Alzheimer’s disease risk that ... Alzheimer’s disease interventions, according to an article published July ... this study represents one of several pieces that have ... of years,” Ethell said. , The study, “Women with ...
(Date:7/29/2014)... Most people want to turn back the clock on aging. ... appearance. There are anti aging microcurrent facials and ... help them to look their absolute best. Supreme Skin ... procedures that are noninvasive and they adding some body treatments ... To accommodate, they are also in the process of ...
(Date:7/29/2014)... to cure most cases of cancer is to surgically ... however, is that the surgeon may fail to extract ... With a new technique, researchers at the University of ... see the entire tumor in the patient, increasing the ... an injectable dye that accumulates in cancerous tissues much ...
(Date:7/29/2014)... The report, “Heat Transfer Fluids Market ... Glycol Fluids, & Others), by Application (Oil & Gas, ... - Trends & Forecasts to 2019” defines and segments ... and forecast of the global consumption in terms of ... 64 figures spread through 199 page sand in-depth TOC ...
Breaking Medicine News(10 mins):Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 3Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2Health News:Supreme Skin Announces Plans for a Grand Re-opening for Their Noninvasive Anti Aging Microcurrent Face and Body Treatments In Asheville, NC 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 2Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 3Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 4
... LENA(TM) Developmental Snapshot is back by popular ... quick and easy way to find out ... ).(Logo: http://www.newscom.com/cgi-bin/prnh/20090210/LA69114 )In the summer ... offered the assessment, more than 13,000 people ...
... Uninsured, including those who are recently unemployed, can attend ... expertPITTSBURGH, March 16 As the nation marks National ... Highmark is offering resources to help Pennsylvanians without health ... the Pennsylvania Insurance Department found that the uninsured ranks ...
... A new study published in Epilepsia ... as high in people with epilepsy compared to the ... seven times the odds of depression in comparison to ... 40 percent of depressed respondents with epilepsy were not ...
... be putting themselves at greater risk of breast cancer ... by Dr. Nisa Maruthur and her team from The ... seriously obese women are significantly less likely to say ... women, especially if they are white. Maruthur,s findings are ...
... The following is being released by the National ... "Waste Not, Want Not: The Right Care for Every ... care that not only costs less but is higher ... advocates and other stakeholders to discuss ways to eliminate ...
... Time for Spring Break and Summer MonthsCOLD SPRING HARBOR, N.Y., ... ear health and creator of EarPlanes(R) and ... ClearEars are revolutionary earplugs containing an FDA approved ... the ears after swimming, or even bathing, can lead to ...
Cached Medicine News:Health News:LENA Foundation Revives Popular Online Child Language Assessment Tool 2Health News:LENA Foundation Revives Popular Online Child Language Assessment Tool 3Health News:Highmark Offers Resources to Help Pennsylvanians Without Health Insurance During Cover the Uninsured Week 2Health News:Highmark Offers Resources to Help Pennsylvanians Without Health Insurance During Cover the Uninsured Week 3Health News:Depression twice as likely in seizure sufferers 2Health News:Obese women play cancer roulette 2Health News:Cleveland Conference: Quality Healthcare Can and Should Cost Less 2Health News:Cleveland Conference: Quality Healthcare Can and Should Cost Less 3Health News:Cleveland Conference: Quality Healthcare Can and Should Cost Less 4Health News:Cleveland Conference: Quality Healthcare Can and Should Cost Less 5Health News:Leader in Ear Care Health Category Expands Product Line 2
(Date:7/29/2014)... LAKE CITY , July 29, 2014  The ... The Grand American Hotel in Salt Lake ... speakers representing some of most respected healthcare organizations in ... Health Catalyst , is an industry conference devoted to ... healthcare analytics,  an essential element of both accountable care ...
(Date:7/29/2014)... , July 29, 2014  Novation, a ... web-based applications with breakthrough interactive features that automate ... for members of Children,s Hospital Association.  ... Novation Optimize Solutions umbrella – Value Analysis, Item ... Novation helps organizations address the most critical challenges ...
(Date:7/29/2014)... , July 29, 2014   Abide Therapeutics ... Thornberry to its board of directors. Thornberry ... Diabetes and Endocrinology for Merck & Co. Inc., ... overall pipeline management in diabetes, osteoporosis, fertility and ... co-led the program that resulted in the discovery ...
Breaking Medicine Technology:Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3
... Wound Care Innovations, LLC,a subsidiary of Wound ... an evidence based study with a NE podiatric ... care collagen,product, CellerateRx(R), on diabetic venous ulcers. "According ... and Prevention, diabetes now,affects nearly 24 million people ...
... Clinical Program Leverages Quark,s RNAi Technology, FREMONT, ... pharmaceutical company discovering and developing novel,RNA interference (RNAi)-based ... patient dosing in a Phase II trial,evaluating, ... (DME)., PF-4523655 is a novel siRNA drug ...
Cached Medicine Technology:Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers 2Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 2Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 3Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 4
... are available in two tip ... tip with staggered eyes, and ... types of catheter valve options, ... fingertip control with virtually no ...
... are available in two tip ... tip with staggered eyes, and ... types of catheter valve options, ... fingertip control with virtually no ...
Sterile Single Loop Pediatric Suction Catheters with TOUCH-TROL Valve...
Catheter Suction 14FR Sterile W/Control Valve...
Medicine Products: